Struggling bluebird aims to raise funds through stock sale, unusual financing deal

Typically, a new drug approval — and the third in just two years’ time — is good news for a biopharmaceutical company. Not so for bluebird bio Inc., whose new sickle-cell gene therapy is not going quite according to plan.